EXAS Stock Recent News

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2025 webcast & conference call details Date: Thursd.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening.

EXAS' solid focus on advancing new solutions bodes well for investors. However, a dull macroeconomic condition adds to the worry.

Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time

BAAR, Switzerland--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score® test at the 19th St. Gallen International Breast Cancer Conference in Vienna, Austria. A UK study1 explored the benefits of shifting the testing point to the pre-surgery setting by utilizing Oncotype DX on breast cancer core biopsy samples instead of surgical speci.

If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.

Warren Buffett, arguably the greatest investor of all time, once said it is wise for investors to be fearful when others are greedy. One way to apply this advice from the Oracle of Omaha is to look at a soaring stock market and identify companies that aren't performing nearly as well -- or are just performing poorly -- but still have attractive prospects.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. TD Cowen Health Care Conference, Boston Fireside chat on Monday, March 3, 2025 at 10:30 a.m. ET Raymond James Institutional Investors Conference, Orlando Presentation on Tuesday, March 4, 2025 at 1:05 p.m. ET The webcasts can be acces.

Exact Sciences posted strong Q4 revenue growth but faced a significant EPS miss due to an $838M impairment charge from the Thrive acquisition. Despite the negative market reaction, Exact's core business shows momentum, with strong demand for Cologuard and a solid cash position of $1.04B. The company has ambitious 2025 revenue guidance and expects new product launches to drive growth, aiming for sustained profitability and long-term value.

Exact Sciences' fourth-quarter 2024 performance benefits from the robust momentum in Cologuard adoption.